CYTH - Cyclo Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Gainesville,
United States
Type: Equity
CYTH price evolution
CYTH
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.12 | $3 | $9.25 | |
| Short term investments | ||||
| Net receivables | $0.19 | $0.08 | $0.07 | $0.12 |
| Inventory | $0.24 | $0.24 | $0.24 | $0.25 |
| Total current assets | $3.26 | $4.45 | $6.57 | $12.32 |
| Long term investments | ||||
| Property, plant & equipment | $0.05 | $0.27 | $0.59 | $0.93 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.27 | $0.59 | $0.93 | |
| Total investments | ||||
| Total assets | $5.25 | $4.72 | $7.16 | $13.25 |
| Current liabilities | ||||
| Accounts payable | $5.79 | $5.54 | $4.79 | $7.46 |
| Deferred revenue | ||||
| Short long term debt | $2.98 | $0.65 | $1.01 | |
| Total current liabilities | $18.72 | $9.83 | $6.54 | $8.47 |
| Long term debt | $0.01 | $0.02 | $0.02 | |
| Total noncurrent liabilities | $0.01 | $0.02 | $0.02 | |
| Total debt | $3 | $0.67 | $1.03 | |
| Total liabilities | $18.73 | $9.84 | $6.55 | $8.49 |
| Shareholders' equity | ||||
| Retained earnings | -$103.01 | -$94.18 | -$88.2 | -$83.86 |
| Other shareholder equity | ||||
| Total shareholder equity | -$5.12 | $0.61 | $4.76 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $9.25 | $1.54 | $16.61 | $12.85 |
| Short term investments | $0.05 | $0.04 | ||
| Net receivables | $0.12 | $0.05 | $0.49 | $0.07 |
| Inventory | $0.25 | $0.25 | $0.23 | $0.24 |
| Total current assets | $12.32 | $4.16 | $19.44 | $14.05 |
| Long term investments | $0.01 | $0.05 | ||
| Property, plant & equipment | $0.93 | $0.06 | $0.08 | $0.09 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.93 | $0.06 | $0.08 | $0.14 |
| Total investments | $0.05 | $0.09 | ||
| Total assets | $13.25 | $4.22 | $19.52 | $14.19 |
| Current liabilities | ||||
| Accounts payable | $5.77 | $3.48 | $3.68 | $3.54 |
| Deferred revenue | ||||
| Short long term debt | $1.01 | $0.15 | $0.13 | |
| Total current liabilities | $8.47 | $3.48 | $3.83 | $3.67 |
| Long term debt | $0.02 | $0.02 | $0.06 | |
| Total noncurrent liabilities | $0.02 | $0.02 | $0.06 | |
| Total debt | $1.03 | $0.17 | $0.19 | |
| Total liabilities | $8.49 | $3.48 | $3.85 | $3.74 |
| Shareholders' equity | ||||
| Retained earnings | -$83.86 | -$63.8 | -$48.35 | -$34.06 |
| Other shareholder equity | ||||
| Total shareholder equity | $4.76 | $0.73 | $15.67 | $10.45 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.23 | $0.12 | $0.2 | $0.31 |
| Cost of revenue | $0.01 | $0.01 | $0.02 | |
| Gross Profit | $0.21 | $0.11 | $0.19 | $0.3 |
| Operating activities | ||||
| Research & development | $3.49 | $2.85 | $4.14 | |
| Selling, general & administrative | $1.86 | $1.82 | $1.34 | |
| Total operating expenses | $8.5 | $5.75 | $5.31 | $5.94 |
| Operating income | -$5.64 | -$5.12 | -$5.64 | |
| Income from continuing operations | ||||
| EBIT | -$5.98 | -$4.34 | -$5.64 | |
| Income tax expense | ||||
| Interest expense | $0.55 | |||
| Net income | ||||
| Net income | -$8.83 | -$5.98 | -$4.34 | -$5.64 |
| Income (for common shares) | -$5.98 | -$4.34 | -$5.64 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.08 | $1.38 | $1.59 | $0.9 |
| Cost of revenue | $0.08 | $0.14 | $0.16 | $0.07 |
| Gross Profit | $0.99 | $1.24 | $1.43 | $0.84 |
| Operating activities | ||||
| Research & development | $14.18 | $9 | $9.15 | $6.1 |
| Selling, general & administrative | $4.9 | $5.41 | $5.05 | $3.15 |
| Total operating expenses | $21.04 | $16.86 | $15.72 | $9.8 |
| Operating income | -$20.05 | -$15.62 | -$14.29 | -$8.96 |
| Income from continuing operations | ||||
| EBIT | -$20.06 | -$15.45 | -$14.29 | -$8.94 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$20.06 | -$15.45 | -$14.29 | -$8.94 |
| Income (for common shares) | -$20.06 | -$15.45 | -$14.29 | -$8.94 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$5.98 | -$4.34 | -$5.64 | |
| Operating activities | ||||
| Depreciation | $0 | $0 | $0 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.27 | $0.27 | $0.26 | |
| Total cash flows from operations | -$3.85 | -$6.18 | -$4.29 | |
| Investing activities | ||||
| Capital expenditures | -$0 | |||
| Investments | ||||
| Total cash flows from investing | -$0 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.51 | |||
| Net borrowings | $2 | |||
| Total cash flows from financing | $9.9 | $1.97 | -$0.07 | $11.74 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$8.32 | -$1.87 | -$6.25 | $7.44 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$20.06 | -$15.45 | -$14.29 | -$8.94 |
| Operating activities | ||||
| Depreciation | $0.02 | $0.02 | $0.02 | $0.01 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.74 | $0.51 | $0.47 | |
| Total cash flows from operations | -$16.19 | -$15.11 | -$15.01 | -$8.54 |
| Investing activities | ||||
| Capital expenditures | -$0 | -$0.02 | -$0.02 | -$0.05 |
| Investments | $0.05 | $0.04 | $0.04 | |
| Total cash flows from investing | -$0 | $0.04 | $0.01 | -$0.01 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $9.74 | $18.76 | $18.46 | |
| Net borrowings | $0.01 | -$0.01 | $0.16 | |
| Total cash flows from financing | $23.89 | $0.01 | $18.76 | $18.62 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $7.7 | -$15.07 | $3.77 | $10.06 |
News
Fundamentals
| Market cap | $17.84M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 28.77M |
| Revenue | $870.72K |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$24.80M |
| Revenue Q/Q | -52.82% |
| Revenue Y/Y | -8.52% |
| P/E ratio | -0.72 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 20.48 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.86 |
|---|---|
| ROA | -326.49% |
| ROE | N/A |
| Debt/Equity | 1.78 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.17 |
| Quick ratio | 0.16 |